Aurobindo’s Eugia subsidiary obtains FDA nod for generic Depo-Testosterone injection

Aurobindo Pharma’s subsidiary, Eugia Pharma Specialities, has received the Food and Drug Administration’s permission for Testosterone Cypionate Injection 1,000 mg/10 ml (100 mg/ml) and 2,000 mg/10 ml (200 mg/ml) in Multi-Dose Vial and 200 mg/ml in Single-Dose Vial, which is the generic of  Pfizer’s Depo-Testosterone Injection.

The product, which is expected to be launched in November 2023, has a market value of roughly $226.8 million for the 12 months ending August 2023, per IQVIA.

[Read more: Aurobindo gets FDA nod for 3 generics]

Testosterone Cypionate Injection is indicated replacement therapy in males in conditions associated with symptoms of deficiency or absence of endogenous testosterone, Primary hypogonadism (congenital or acquired) and Hypogonadotropic hypogonadism (congenital or acquired).

[Read more: Aurobindo receives FDA OK for generic Renagel]